CABG Clinical Trial - Empagliflozin to Prevent Post-Operative Atrial

Status Recruiting

Clinical Trial Summary

This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication. The goal of present study is to investigate if periprocedural administration of 10 mg once daily empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2I), can reduce the incidence of post-operative atrial fibrillation and/or atrial flutter in patients with chronic coronary syndrome scheduled for isolated CABG. This trial will be conducted in two referral teaching cardiology hospitals in Tehran. 492 adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting 3 days before surgery until discharge.

Clinical Trial Description

Study aim: Evaluating the role of empagliflozin on the rate of postoperative atrial fibrillation in comparison with placebo Design: Two arms, parallel-group, phase 3, randomized, double-blind, placebo-controlled trial on 492 patients Settings and conduct: Recruitment site: Tehran Heart Center and Rajaie Cardiovascular Medical and Research Center For blinding, the drug or placebo will be given to the ward based on the patient's code in the randomization system For monitoring, the blood samples for creatinine, sodium, potassium, and fasting blood sugar along with clinical evaluations will be given on day 0 and daily thereafter (max= 30 days) in specific wards and will be compared at the end of any atrial fibrillation lasting longer than 30 seconds based on 24-hour 12-lead ECG monitoring will be accepted as atrial fibrillation After entering the study, the patients are placed in one of two groups, sample and control; in the sample group, they are treated with the usual treatment regimen plus empagliflozin at a dose of 10 mg during the hospitalization period. Patients in the control arm will receive a matching placebo. ;

Study Design

Related Conditions & MeSH terms

Atrial Fibrillation
CABG
Post-operative Atrial Fibrillation

Clinical Trial Details

NCT number	NCT06124937
Study type	Interventional
Source	Rajaie Cardiovascular Medical and Research Center
Contact	Hessam Kakavand, PharmD
Phone	+982144605351
Email	hessamkakavand@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	November 7, 2023
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01956708` - Transfer of Cardioprotection During RIPC	N/A
Completed	`NCT01928745` - Experimental Determination of Atot en Ka in the Critically Ill	N/A
Active, not recruiting	`NCT00966654` - Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery	Phase 2
Completed	`NCT00524901` - Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia	Phase 2
Completed	`NCT01282671` - Effects of Deep Breathing Exercises Two Months After Cardiac Surgery	Phase 2
Completed	`NCT03050489` - Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Completed	`NCT00269243` - Management With Accupril Post Bypass Graft	Phase 4
Recruiting	`NCT03139929` - Measurement of MSFP and Stressed Volume With CardioQ+®
Active, not recruiting	`NCT03424941` - The TransCatheter Valve and Vessels Trial	N/A
Completed	`NCT06317363` - Effects of Acapella VS CHEST Physiotherapy in Post-Operative CABG Patients	N/A
Completed	`NCT05023083` - Cross Cultural Adaptation of Functional Status Questionnaire in Urdu Language in CABG Patients
Completed	`NCT03800264` - Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery	Phase 4
Completed	`NCT05285865` - Scapular Mobilization on Inspiratory Capacity of Post-CABG Patients	N/A
Not yet recruiting	`NCT06173609` - Long LIMA Patch on Left Anterior Descending Coronary Artery in CABG
Not yet recruiting	`NCT06238011` - Dexmedetomidine vs Control on Attenuation Hemodynamic Response to Noxious Stimuli in CABG Surgical Patients	N/A
Active, not recruiting	`NCT06127147` - High-intensity Inspiratory Muscle Training as a Pre-cardiac Rehabilitation in Heart Disease	N/A
Recruiting	`NCT06029556` - Effects of Early Mobility Protocols in Cardiac ICU	N/A
Enrolling by invitation	`NCT01205620` - IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Empagliflozin to Prevent Post-Operative Atrial Fibrillation — EMPOAF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms